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Abstract
Purpose Preventing chemotherapy-induced nausea and
vomiting (CINV) is integral to treatment success in patients
with cancer. This analysis was undertaken to assess the rela-
tive efficacy and safety of palonosetron versus older 5HT3
RAs in preventing CINVassociated with moderately or highly
emetogenic chemotherapy.
Methods Patient-level data from four randomized, double-
blind, phase III trials comparing palonosetron 0.25 or
0.75 mg with ondansetron 32 mg, dolasetron 100 mg, or
granisetron 40μg/kgwere analyzed. Endpoints included com-
plete response (CR: no emesis and no rescue antiemetics) in
the acute (0–24 h), delayed (>24–120 h), and overall (0–
120 h) postchemotherapy periods (primary), complete control
(CC: no emesis, no rescue antiemetics, and no more than mild
nausea), number of emetic episodes, and nausea severity.
Results CR rates were significantly higher for palonosetron
(n =1,787) versus older 5HT3 RAs (n =1,175) in the delayed
(57 vs 45 %, P <0.0001) and overall periods (51 vs 40 %, P <
0.0001); odds ratios (95 % CI) in the acute, delayed, and
overall periods were 1.15 (0.98–1.34), 1.62 (1.40–1.88), and
1.56 (1.34–1.81), respectively. Significant differences in CC
rates and nausea severity were observed for the delayed and
overall periods and in emetic episodes for all three periods.
The incidence of treatment-related adverse events was similar
with palonosetron (0.25 mg, 20.0 %; 0.75 mg, 26.5 %) and
older 5HT3 RAs (27.5 %).
Conclusions Palonosetron is more effective than older 5HT3
RAs for controlling CINV in the delayed and overall post-
chemotherapy periods.
Keywords Palonosetron . Serotonin antagonists . CINV .
Nausea . Vomiting . Cancer chemotherapy
Introduction
Patients with cancer who receive chemotherapy often experi-
ence nausea and vomiting (chemotherapy-induced nausea and
vomiting, CINV), the onset of which can be acute (starting
within minutes to hours following treatment and generally
resolving within 24 h) or delayed (starting more than 24 h
after treatment and lasting for up to several days) [1]. The time
course and severity of CINV vary depending on the specific
chemotherapeutic agents administered, their dosages and
routes of administration, and patient factors such as age,
gender, history of alcohol use, and type of cancer [1–3].
Delayed CINV, which tends to be more common than acute
CINV, is less responsive to antiemetic therapy [4, 5]. Delayed
nausea also tends to be more severe than acute nausea [4, 5].
Although delayed nausea can occur in the absence of acute
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CINV [6], both types are important targets for antiemetic
therapy because the risk of delayed CINV is greater if acute
CINV is poorly controlled [7]. Further, the risk of CINV in
general is highly related to its occurrence in a previous cycle
of chemotherapy [8, 9].
Adverse consequences of CINV may include metabolic
derangements, nutritional deficiencies and anorexia, esopha-
geal tears, wound dehiscence, deterioration of performance
andmental status, and degeneration of self-care and functional
ability [1]. Further, CINV may lead to the discontinuation of
potentially beneficial or curative anticancer treatments [1] and
significantly affects quality of life [9]. Controlling CINV is
therefore integral to treatment success in patients with cancer.
The first generation of 5HT3 receptor antagonists (5HT3
RAs), such as ondansetron, dolasetron, and granisetron revo-
lutionized CINV management. These antiemetic agents are
broadly effective in controlling acute CINV associated with
moderately (MEC) or highly emetogenic chemotherapy
(HEC) [10].
The 5HT3 RA palonosetron differs from other 5HT3 RAs in
its pharmacokinetic/pharmacodynamic profile and may be
uniquely suited to treat delayed CINV. Specifically, palonosetron
has a longer elimination half-life (t½) and a distinctly different
receptor-binding profile compared with older 5HT3 RAs [11],
uniquely triggers 5HT3 receptor internalization, and induces
prolonged inhibition of receptor function [12]. Palonosetron also
inhibits substance P responses in a serotonin-independent man-
ner [13].
In the clinical setting, palonosetron improved rates of
CINV prevention relative to older 5HT3 RAs in four phase
III trials in patients receiving either MEC (30–90% frequency
of emesis) [14, 15] or HEC (>90 % frequency of emesis) [16,
17]. The present analysis utilized pooled data from these four
trials to compare the relative effectiveness of palonosetron
versus older 5HT3 RAs for preventing CINV in patients with
cancer scheduled to receive either MEC or HEC and to
compare the tolerability of palonosetron with that of older
5HT3 RAs. These studies were selected because patient-
level data were available for analysis.
Patients and methods
Pooled patient-level data from four multicenter, randomized,
double-blind, parallel-group phase III trials were analyzed
(Table 1). Two of the trials were conducted in patients sched-
uled to receive MEC [14, 15] and two in patients scheduled to
receive HEC [16, 17]. Of note, 64% of patients in the study by
Eisenberg et al. received anthracycline+cyclophosphamide
(AC) [15], which is currently classified as HEC [1] (at the
time of the study, AC was classified as MEC). Three trials
were conducted in Europe or North America [14–16] and one
in Japan [17]. All four studies were approved by institutional
review boards or independent ethics committees at each site
where they were performed. Written informed consent was
obtained from all participating patients before any study-
related procedure was initiated.
Methods of included trials
The methods for each study have been described in detail
[14–17]. Briefly, patients enrolled in the four studies were
Table 1 Studies pooled for analysis (all were randomized, double-blind, controlled clinical trials)
Study 5HT3 RA treatment groups
a N (ITT) Emetogenicity of chemotherapy
Gralla et al. [14] Palonosetron 0.25 mg 189 MEC
Palonosetron 0.75 mg 189
Ondansetron 32 mg 185
Eisenberg et. al [15] Palonosetron 0.25 mgb 189 MEC
Palonosetron 0.75 mgb 189
Dolasetron 100 mgb 191
Aapro et al. [16] Palonosetron 0.25 mgb 223 HEC
Palonosetron 0.75 mgb 223
Ondansetron 32 mgb 221
Saito et al. [17] Palonosetron 0.75 mgc 555 HEC
Granisetron 40 μg/kgc 559
5HT3 RA 5HT3 receptor antagonist, HEC highly emetogenic chemotherapy, ITT intent-to-treat, IV intravenously, MEC moderately emetogenic
chemotherapy
aAll 5HT3 RAs were administered as a single IV dose 30 min before the scheduled chemotherapy regimen
b Patients could also receive dexamethasone (20 mg IV, 15 min before chemotherapy)
c All patients also received dexamethasone (16 mg IV, 45 min before 5HT3 RAs, plus another IV [8 mg] or oral dose [4 mg] on days 2 and 3 after
chemotherapy)
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required to be at least 18 years of age, have a histologically or
cytologically confirmed malignancy, and have a Karnofsky
Performance Scale score of ≥50 %. Eligible patients were
randomly assigned to receive single intravenous (IV) doses
of palonosetron (0.25 or 0.75 mg) or older 5HT3 RAs:
ondansetron (32 mg), dolasetron (100 mg), and granisetron
(40 μg/kg), all of which were administered 30 min before the
scheduled chemotherapy regimens. Consistent with guide-
lines at the time of the studies, concomitant steroids were
permitted [15, 16] or required [17] in three of the four studies.
In each study, the primary efficacy endpoint was the complete
response (CR) rate (defined as no emesis and no rescue
medication) in the acute (0–24 h), delayed (>24–120 h), and/
or overall (0–120 h) postchemotherapy treatment periods.
Secondary efficacy endpoints included the complete control
(CC) rate (defined as no emesis, no rescue medication, and no
more than mild nausea) during the acute, delayed, and overall
postchemotherapy treatment periods; numbers of emetic and
nausea episodes; and nausea severity (rated on a four-point
Likert scale from 0=none to 3=severe). Safety assessments
included adverse events (AEs), vital signs, laboratory test
results, and electrocardiographic (ECG) findings.
Statistical analysis
For this analysis, data from patients treated with ondansetron,
dolasetron, or granisetron were pooled, and all data from all
patients treated with palonosetron were pooled. Because the
older 5HT3 RAs have similar efficacy in preventing CINV
when administered at therapeutically equivalent doses [10],
pooling of the data for these agents was considered valid.
Similarly, as there are few differences in efficacy between
the 0.25- and 0.75-mg doses of palonosetron [14–16], pooling
of data for the two doses was also considered valid.
A logistic regression model was used to analyze pooled data
from the four phase III trials and was fitted for CR and CC
endpoints with terms for palonosetron 0.25, palonosetron 0.75,
HEC, MEC, and Japanese study. In addition, a goodness-of-fit
test (Hosmer–Lemeshow) was applied to ensure the consisten-
cy of effect of the endpoint across various strata of variables in
the model. Interaction terms were assessed for significance. If
the term was deemed not significant, it was removed from the
model. The model was then refitted, and the model-fit and
goodness-of-fit tests were reapplied. This process was repeated,
eliminating each nonsignificant variable, one at a time, until all
nonsignificant variables had been eliminated or the Hosmer–
Lemeshow goodness-of-fit test had become significant. The
process also was repeated for the subgroups of patients who
had lung cancer or breast cancer. For descriptive purposes, if
both the model-fit and Hosmer–Lemeshow goodness-of-fit
tests were statistically significant (suggesting poor model fit
across the strata, even though the model fit was good), the
statistically significant model was displayed with a note of
pooled consistency of fit across various strata (i.e., a statistically
significant Hosmer–Lemeshow goodness-of-fit test statistic).
Observed rates of each efficacy outcome were compared
between the palonosetron (pooled doses) and older 5HT3 RA
groups using Cochran–Mantel–Haenszel tests.
For the safety analyses, a comparative descriptive assess-
ment of AE rates in the four studies was performed.
Results
A total of 2,962 patients were included in the analysis: 1,787
received palonosetron and 1,175 received older 5HT3 RAs.
Demographic and clinical characteristics of the analysis pop-
ulation are shown in Table 2. Data are shown separately for
MEC and HEC studies. Additionally, data are shown for
patients who received AC treatment in any study. Mean body
weight was slightly lower in the groups containing Japanese
patients in the study of HEC-induced CINV [17]. The major-
ity of patients receiving HEC also received a corticosteroid
(dexamethasone) concomitantly, while the majority of patients
receiving MEC did not (Table 2); all patients in the Saito et al.
study [17], approximately 67 % of patients in the Aapro et al.
study [16], 5 % of patients in the Eisenberg et al. study [15]),
and no patients in the Gralla et al. study [14] received
corticosteroids.
Complete response rates
CR rates were significantly higher for palonosetron (pooled
doses) relative to older 5HT3 RAs during the delayed phase
(P <0.0001), and overall phase (P <0.0001), but not the acute
phase (P=0.091) (Fig. 1a). Likewise, odds ratios (ORs, 95 %
CI) reflected a significantly greater likelihood of CR with
palonosetron versus older 5HT3 RAs in the delayed (OR,
1.62 [1.40–1.88]) and overall phases (OR, 1.56 [1.34–1.81]),
but not the acute phase (OR, 1.15 [0.98–1.34]).
Complete control rates
Analysis of the CC data showed that palonosetron provided
higher CC rates than older 5HT3 RAs in the delayed (P <
0.0001) and overall (P <0.0001) phases, but not the acute
phase (P=0.137) (Fig. 1b). ORs (95 % CI) for the acute,
delayed, and overall phases were 1.12 (0.96–1.31), 1.49
(1.29–1.73), and 1.50 (1.29–1.74), respectively.
Number of emetic episodes
The frequency of emetic episodes was significantly differ-
ent for palonosetron and older 5HT3 RAs during the acute
(P=0.007), delayed (P <0.0001), and overall (P <0.0001)
phases (Fig. 2).
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Table 2 Pooled demographic and clinical characteristics of patients treated with palonosetron (PALO) or other 5HT3 RAs in four randomized controlled



































Age (year), mean (SD) 55.0 (12.1) 54.6 (12.0) 55.6 (12.4) 56.0 (12.1) 52.1 (11.1) 51.9 (10.9) 55.3 (12.3) 55.6 (12.1)
Height (cm), mean (SD) 162.6 (9.0) 163.0 (8.9) 161.9 (9.4) 161.1 (9.4) 159.5 (7.7) 158.5 (7.8) 162.2 (9.2) 161.7 (9.3)
Weight (kg), mean (SD) 70.9 (15.1) 71.8 (15.8) 62.5 (13.3) 60.7 (12.7) 66.4 (14.7) 63.2 (14.4) 66.1 (14.7) 64.3 (14.7)
Gender, n (%)
Male 173 (23) 88 (23) 460 (45) 347 (44) 54 (7) 25 (5) 633 (35) 435 (37)
Female 592 (77) 293 (77) 562 (55) 447 (56) 694 (93) 470 (95) 1,154 (65) 740 (63)
Alcohol use, n (%)
None 426 (56) 215 (56) 467 (46) 362 (46) 555 (74) 363 (73) 893 (50) 577 (49)
Rarely 203 (27) 98 (26) 200 (20) 132 (17) 96 (13) 73 (15) 403 (23) 230 (20)
Occasionally/sometimes 100 (13) 43 (11) 149 (15) 113 (14) 97 (13) 59 (12) 249 (14) 156 (13)
Regularly/daily 34 (5) 25 (7) 205 (20) 187 (24) 555 (74) 363 (73) 239 (13) 212 (18)
Tobacco use, n (%)
Nonsmoker 506 (66) 242 (64) 469 (46) 361 (46) 555 (74) 363 (73) 975 (55) 603 (51)
Ex-smoker 137 (18) 74 (19) 377 (37) 312 (39) 96 (13) 73 (15) 514 (29) 386 (33)
Smoker 121 (16) 65 (17) 175 (17) 121 (15) 97 (13) 59 (12) 296 (17) 186 (16)
Corticosteroid use, n (%)
Yes 23 (3) 8 (2) 861 (85) 711 (91) 268 (36) 257 (52) 884 (50) 719 (62)
No 742 (97) 373 (98) 149 (15) 74 (9) 480 (64) 238 (48) 891 (50) 447 (38)
Primary cancer, n (%)
Blood 44 (6) 22 (6) 51 (5) 22 (3) 48 (6) 23 (5) 95 (5) 44 (4)
Breast 469 (61) 241 (63) 262 (26) 256 (32) 635 (85) 446 (90) 731 (41) 497 (42)
CNS 1 (<1) 2 (1) 4 (<1) 1 (<1) 0 0 5 (<1) 3 (<1)
Colorectal 42 (6) 12 (3) 7 (1) 3 (<1) 0 0 49 (3) 15 (1)
Endocrine 7 (1) 3 (1) 12 (1) 5 (1) 3 (<1) 0 19 (1) 8 (1)
GI 13 (2) 8 (2) 24 (2) 15 (2) 1 (<1) 0 37 (2) 23 (2)
Genitourinary 65 (9) 34 (9) 147 (14) 76 (10) 27 (4) 8 (2) 212 (12) 110 (9)
Head and neck 12 (2) 7 (2) 77 (8) 32 (4) 2 (<1) 3 (1) 89 (5) 39 (3)
Hepatobiliary 8 (1) 2 (1) 4 (<1) 1 (<1) 0 0 12 (1) 3 (<1)
Respiratory 84 (11) 37 (10) 384 (38) 343 (43) 22 (3) 9 (2) 468 (26) 380 (32)
Sarcoma 7 (1) 7 (2) 11 (1) 6 (1) 7 (1) 2 (<1) 18 (1) 13 (1)
Skin 5 (1) 2 (1) 22 (2) 17 (2) 0 1 (<1) 27 (2) 19 (2)
5HT3 RAs other 5HT3 receptor antagonists (ondansetron, dolasetron, or granisetron), Dex dexamethasone, ITT intent-to-treat, IV intravenous, PALO
palonosetron
a Agents associated with a 30–90 % frequency of emesis [1]
b Agents associated with >90 % frequency of emesis [1]
c Patients who received AC chemotherapy in any of the four studies
d Pooled data for the palonosetron 0.25 and 0.75 mg arms, and the other 5HT3 RA (ondansetron 32mg and dolasetron 100mg) arms of the two studies of
moderately emetogenic chemotherapy [14, 15]
e Pooled data for the palonosetron 0.25 mg and/or 0.75 mg ± dexamethasone arms, and the other 5HT3 RA (ondansetron 32 mg ± dexamethasone and
granisetron 40 μg/kg + dexamethasone) arms of the two studies of highly emetogenic chemotherapy [16, 17]
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Frequency and severity of nausea episodes
The severity of nausea episodes was not significantly different
with palonosetron and older 5HT3 RAs during the acute
postchemotherapy phase (P=0.165). However, there were sig-
nificant differences in the delayed (P=0.0002) and overall
phases (P=0.011) (Fig. 3). In terms of frequency of nausea, in
the acute phase, 56% of the palonosetron group and 54% of the
older 5HT3 RA group reported no episodes of nausea; in the
delayed phase, the rates were 44 and 36 %, respectively, and in
the overall phase, the rates were 39 and 33 %, respectively.
Safety and tolerability
The incidence of treatment-related AEs was similar for the three
overall treatment groups: palonosetron 0.25 mg (20.0 %),
palonosetron 0.75 mg (26.5 %), and older 5HT3 RAs (27.5 %)
(Table 3). The percentages of patientswith treatment-relatedAEs
was less than one third of the percentages of patients with all-
cause AEs, suggesting that most reported AEs were likely due to
the patients’ cancer and/or the chemotherapy regimens (Table 3).
The most common treatment-related AEs were constipation
(palonosetron 0.25 mg [4.4 %], palonosetron 0.75 mg
[11.5 %], older 5HT3 RAs [9.2 %]) and headache (palonosetron
0.25mg [9.0%], palonosetron 0.75mg [7.4%], older 5HT3RAs
[7.4 %]) (Table 3).
Discussion
This analysis of pooled patient-level data from four multicenter,
phase III, randomized, double-blind, comparative trials dem-
onstrates that palonosetron has a safety profile similar to that of
older 5HT3 RAs but provides superior prophylaxis of CINV.
















Acute phase (0−24 h) Delayed phase (>24−120 h) Overall phase (0−120 h)
Complete Response Rates








































PALO (n = 1,769) Other 5HT3 RAs (n = 1,164)
*
*
Acute phase (0−24 h) Delayed phase (>24−120 h) Overall phase (0−120 h)
a
b
Fig. 1 a , b Complete response rates for all patients/complete control
rates for all patients. a Significant differences between the palonosetron
and other 5HT3 RAs groups were observed in the delayed and overall
phases. Complete response no emetic episodes and no usage of rescue
medication, PALO palonosetron, other 5HT3 RAs other 5HT3 receptor
antagonists (ondansetron, dolasetron, and granisetron). *P <0.0001,
palonosetron versus other 5HT3 RAs. b Significant differences between
the palonosetron and other 5HT3 RAs groups were observed in the
delayed and overall phases. Complete control no emetic episodes, no
usage of rescue medication, and no more than mild nausea; PALO
palonosetron; other 5HT3 RAs other 5HT3 receptor antagonists
(ondansetron, dolasetron, and granisetron). *P <0.0001, palonosetron







































None 1 2 3 or more
Acute Phase (0−24 h) Delayed Phase (>24−120 h) Overall Phase (0−120 h)
††*
Fig. 2 Episodes of emesis in the
acute, delayed, and overall
postchemotherapy phases.
Significant differences between
the palonosetron and other 5HT3
RAs groups were observed in the
acute, delayed, and overall
phases. PALO palonosetron,




palonosetron versus other 5HT3
RAs; †P<0.0001, palonosetron
versus other 5HT3 RAs
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response (CR) and complete control (CC) rates than older
5HT3 RAs (ondansetron, dolasetron, and granisetron) during
the delayed (>24-120 h), and overall (0–120 h) postchemo-
therapy periods. The number of emetic episodes and severity of
nausea were also significantly different for palonosetron com-
pared with older 5HT3 RAs.
The most noteworthy differences between palonosetron
and older 5HT3 RAs occurred in the delayed phase and
throughout the overall 5-day evaluation period. Palonosetron
therefore provides an effective option for delayed onset CINV,
an effect of chemotherapy that previously had been more
difficult to manage due to the limited efficacy of older 5HT3
RAs in this context [5, 6]. Further, palonosetron may be more
effective in controlling nausea [18] (particularly delayed nau-
sea), which remains a challenge despite the antiemetic
efficacy of the older 5HT3 RAs [19, 20]. The observed ad-
vantage of palonosetron in efficacy during the delayed phase
may be explained by differences in binding characteristics of
palonosetron (i.e., a longer elimination half-life relative to
other 5HT3 RAs [11] and triggering of receptor internalization
leading to prolonged inhibition of receptor function and NK1
cross talk [12]). All of the studies evaluated outcomes follow-
ing a single dose of palonosetron or other 5HT3 RAs given on
day 1 of chemotherapy; outcomes may differ with the use of
multi-day antiemetic treatment regimens.
The incidence of treatment-related AEs with palonosetron
in this analysis was similar to that of older 5HT3 RAs, with a
lower incidence of AEs associated with the 0.25 mg dose of
palonosetron relative to the 0.75 mg dose. The most common
treatment-related AEs were constipation and headache. Safety
concerns with 5HT3 RAs include the potential for QTc pro-
longation [21], which has been the subject of recent safety
communications from the US FDA (dolasetron: http://www.
fda.gov/Drugs/DrugSafety/ucm237081.htm; ondansetron:
http://www.fda.gov/Drugs/DrugSafety/ucm271913.htm).
Notably, QTc prolongation with ondansetron appears to be
dose dependent, which led to the removal of the 32-mg IV
single daily dose from the ondansetron label (http://www.fda.
gov/Safety/MedWatch/SafetyInformation/SafetyAlerts
forHumanMedicalProducts/ucm310219.htm). IV dolasetron
is no longer recommended due to an increased risk of
cardiac arrhythmias [1]. Notably, recent studies evaluating
the electrocardiographic effects of palonosetron in cancer
patients found no significant changes in QTc interval [22,
23], and a thorough ECG study using moxifloxacin as a
positive control found that doses up to 2.25 mg were not
associated with clinically significant changes in QTc or other
ECG parameters [24].
The efficacy findings are similar to those reported in other









































Acute Phase (0−24 h) Delayed Phase (>24−120 h) Overall Phase (0−120 h)
Fig. 3 Severity of nausea in the
acute, delayed, and overall
postchemotherapy phases.
Significant differences between
the palonosetron and other 5HT3
RAs groups were observed in the
delayed and overall phases.PALO
palonosetron, other 5HT3 RAs
other 5HT3 receptor antagonists
(ondansetron, dolasetron, and
granisetron). *P=0.0002,
palonosetron versus other 5HT3
RAs; †P=0.0112, palonosetron
versus other 5HT3 RAs
Table 3 Pooled safety data from the four randomized, double-blind
studies comparing single IV doses of palonosetron with other 5HT3











Total AEs (all-cause), n (%) 425 (69.8) 1,004 (84.9) 985 (83.6)
Treatment-related AEs, n (%) 122 (20.0) 313 (26.5) 324 (27.5)
Most common treatment-related AEsb, n (%)
Constipation 27 (4.4) 136 (11.5) 108 (9.2)
Headache 55 (9.0) 87 (7.4) 87 (7.4)
ALT increased 1 (0.2) 25 (2.1) 37 (3.1)
Other 5HT3 RAs other 5HT3 receptor antagonists (ondansetron,
dolasetron, or granisetron), AE adverse event, ALT alanine aminotrans-
ferase, PALO palonosetron
a Ondansetron 32 mg, dolasetron 100 mg, or granisetron 40 μg/kg
bAdverse events occurring in ≥3 % of patients in any treatment group
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older 5HT3 RAs (ondansetron, dolasetron, and granisetron)
in preventing CINV in patients receiving MEC or HEC
[25–27]. For example, the analysis by Botrel, which includ-
ed data from 2,057 patients from five randomized, double-
blind, comparative trials, showed that palonosetron 0.25 mg
is significantly more effective than older 5HT3 RAs in
preventing both acute and delayed nausea and vomiting,
regardless of the concomitant use of corticosteroids [25].
The relative risks (RRs, 95 % CI) were 0.86 (0.76–0.96,
P=0.007) for acute nausea, 0.82 (0.75–0.89; P <0.00001)
for delayed nausea, 0.76 (0.66–0.88; P=0.0002) for acute
vomiting, and 0.76 (0.68–0.85, P <0.00001) for delayed
vomiting [25]. Likun et al. [27] analyzed data from eight
clinical trials (n =3,592) and found that palonosetron (0.25
and 0.75 mg, combined) was significantly more effective
than first-generation 5HT3 RAs in preventing CINV in the
acute (OR: 0.76 [0.66–0.88], P=0.0003), delayed (OR:
0.62 [0.54–0.71], P <0.00001), and overall phases (OR
0.64 [0.56–0.74], P <0.00001). Most recently, an analysis
of data from nine studies (n =3,463) demonstrated signifi-
cantly greater efficacy with palonosetron 0.25 mg (based on
RR for complete response) compared with first-generation
5HT3 RAs in the acute (1.11 [1.05–1.17]), delayed (1.26
[1.16–1.36]), and overall phases (1.25 [1.14–1.37]) [26].
Results were similar for palonosetron 0.75 mg [26]. These
previous meta-analyses included data from the four studies
analyzed here, as well as data from additional studies.
Limiting our analysis to the pivotal clinical trials that
formed the basis for FDA approval of palonosetron poten-
tially introduces some degree of bias, as not all publicly
available data were included. Other meta-analyses, which
analyzed both abstracted (literature-based) data and patient-
level data, yielded similar results, demonstrating similar
efficacy and safety of the 0.25 and 0.75 mg doses of
palonosetron. This analysis is generally in agreement with
other meta-analyses and utilizes patient-level data to dem-
onstrate a benefit for palonosetron compared with older
5HT3 RAs. We would not expect substantially different
results were the other published studies included.
The overall body of evidence supporting the efficacy of
palonosetron in managing CINV has led to its inclusion in
several clinical practice guidelines. Specifically, the Multina-
tional Association of Supportive Care in Cancer (MASCC),
the European Society of Medical Oncology (ESMO) [19], the
American Society of Clinical Oncology (ASCO) [20], and the
National Comprehensive Cancer Network (NCCN) [1] rec-
ommend palonosetron as the preferred 5HT3 RA for preven-
tion of CINVassociated with MEC. In addition, MASCC and
ESMO recommend palonosetron as the preferred 5HT3 RA
for AC (doxorubicin or epirubicin and cyclophosphamide)
regimens when an NK1 RA is not available [19]. MASCC/
ESMO and ASCO guidelines recommend palonosetron
among other 5HT3 RAs for HEC [19, 20], while NCCN
guidelines denote palonosetron 0.25 mg as the preferred
5HT3 RA for acute and delayed emesis prevention during
intravenous chemotherapy with high emetic risk [1]. Ad-
herence to practice guidelines improves CINV prevention
outcomes; a recent study demonstrated that guideline-
consistent CINV prophylaxis was associated with signifi-
cantly greater odds of CR (OR 1.43 [1.04–1.97]; P=0.027)
[28].
The substantial economic burden associated with manage-
ment of CINV includes resource utilization and costs related to
inpatient, outpatient, and emergency department visits [29, 30].
Improved CINV prevention, therefore, may result in economic
benefits. For example, among patients with breast or lung
cancer on HEC or MEC, the risk of CINV events requiring
hospital or emergency department visits was significantly re-
ducedwith palonosetron as compared to other 5-HT3 RA-based
regimens [31]. Another study demonstrated that palonosetron
was associated with significantly fewer extreme CINV events,
resulting in a substantial reduction in both the use of rescue
antiemetics and staff management time [32]. In addition, be-
cause patients who experience CINV during one cycle of
chemotherapy are more likely to experience CINV in subse-
quent cycles [33], the economic benefits of preventing CINV
during an initial cycle of chemotherapy would be expected to
extend to subsequent cycles.
In summary, the data from the current analysis support
previous findings of improved prevention of CINV relative
to older 5HT3 RAs and further demonstrate an advantage of
palonosetron in preventing delayed CINV. Improved prophy-
laxis against CINV, especially in the first cycle of chemother-
apy, might provide additional benefit in helping to prevent the
occurrence of CINV in subsequent cycles of chemotherapy,
thereby facilitating treatment adherence.
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